- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2013-9-11 21:00 编辑
回复 MP4 的帖子
VGXI manufactures the vaccine for Inovio? VGXI代表Inovio生产疫苗?
Inovio’s DNA vaccine plasmids are produced by Texas-based VGXI, Inc. under a “preferred supplier/client” manufacturing agreement. VGXI produces cGMP-grade plasmid products that have passed rigorous international regulatory reviews and have been used in numerous human clinical trials in the U.S., Europe and Asia. The proprietary process is covered under international patents to enable the production of high quality DNA plasmid products at high concentration. The process allows for final product concentrations up to 15 mg/mL, giving Inovio the ability to maximize the amount of vaccine per injected dose and also facilitates the formulation of multi-component DNA vaccines.
VGXI, Inc. is a subsidiary of VGX International, a Korea-based publicly traded company (Korean Stock Exchange: Stock Ticker Number 011000). Inovio owns a minority share position in VGX International.
位于得克萨斯州的VGXI公司“首选供应商/客户端”制造协议下所产生,Inovio的DNA疫苗质粒。 VGXI生产的产品已经通过了严格的国际监管审查,并在美国,欧洲和亚洲的许多人体临床试验已用于cGMP级的质粒。覆盖下的国际专利专有工艺在高浓度,使生产高品质的DNA质粒产品。的方法,允许最终产品的浓度为15毫克/毫升,Inovio的能力,最大限度地提高每个注射剂量的疫苗的量,也有利于多组分的DNA疫苗的制剂。
VGXI,Inc。是VGX国际的附属公司,一家韩国的上市公司(韩国证券交易所:股票代码011000)。 Inovio拥有少数股份VGX国际地位。
|
|